Reinach, Switzerland, 14 August 2014 – Evolva Holding SA (SIX: EVE) today announces it has entered into a contract (HDTRA1-14-C-0122) with the US Defense Threat Reduction Agency (DTRA) for the program “GC-072: The First Oral Antibiotic for the Treatment of Acute Melioidosis and Select Agents”. DTRA will fund USD 6.5 million for the first 15-month stage and up to an additional USD 8.6 million if the two remaining stages (2 years) are executed.

Evolva continues to pursue options to partner its pharmaceutical pipeline in line with its strategy of focusing on high value ingredients for health, wellness and nutrition.

- ends -

About Evolva

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, vanilla, saffron and resveratrol. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com.

Contact Details

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.